HRP960372B1 - (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate - Google Patents

(1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate

Info

Publication number
HRP960372B1
HRP960372B1 HR960372A HRP960372A HRP960372B1 HR P960372 B1 HRP960372 B1 HR P960372B1 HR 960372 A HR960372 A HR 960372A HR P960372 A HRP960372 A HR P960372A HR P960372 B1 HRP960372 B1 HR P960372B1
Authority
HR
Croatia
Prior art keywords
tridydrate
propanolmethanesulfonate
phenylpiperidin
hydroxyphenyl
hydroxy
Prior art date
Application number
HR960372A
Other languages
English (en)
Inventor
Marta Maria Andino
Terry Gene Sinay
Eugene Fred Fiese
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP960372A2 publication Critical patent/HRP960372A2/hr
Publication of HRP960372B1 publication Critical patent/HRP960372B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HR960372A 1995-08-11 1996-08-09 (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate HRP960372B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (2)

Publication Number Publication Date
HRP960372A2 HRP960372A2 (en) 1998-04-30
HRP960372B1 true HRP960372B1 (en) 2003-04-30

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960372A HRP960372B1 (en) 1995-08-11 1996-08-09 (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate

Country Status (41)

Country Link
US (1) US6008233A (enExample)
EP (1) EP0843661B1 (enExample)
JP (1) JP3099072B2 (enExample)
KR (1) KR100291882B1 (enExample)
CN (2) CN1615861A (enExample)
AP (1) AP755A (enExample)
AR (1) AR004676A1 (enExample)
AT (1) ATE215072T1 (enExample)
AU (1) AU710984B2 (enExample)
BG (1) BG63678B1 (enExample)
BR (1) BR9610766A (enExample)
CA (1) CA2228752C (enExample)
CO (1) CO4750830A1 (enExample)
CZ (1) CZ296236B6 (enExample)
DE (1) DE69620191T2 (enExample)
DK (1) DK0843661T3 (enExample)
DZ (1) DZ2083A1 (enExample)
ES (1) ES2170857T3 (enExample)
GT (1) GT199600051A (enExample)
HR (1) HRP960372B1 (enExample)
HU (1) HUP9802862A3 (enExample)
IL (1) IL122649A (enExample)
IS (1) IS1945B (enExample)
MA (1) MA23957A1 (enExample)
NO (1) NO310458B1 (enExample)
NZ (1) NZ309134A (enExample)
OA (1) OA10664A (enExample)
PE (1) PE4898A1 (enExample)
PL (1) PL185603B1 (enExample)
PT (1) PT843661E (enExample)
RO (1) RO120134B1 (enExample)
RS (1) RS49521B (enExample)
RU (1) RU2140910C1 (enExample)
SA (1) SA96170171B1 (enExample)
SK (1) SK284209B6 (enExample)
TN (1) TNSN96104A1 (enExample)
TR (1) TR199800208T1 (enExample)
TW (1) TW495502B (enExample)
UA (1) UA59341C2 (enExample)
WO (1) WO1997007098A1 (enExample)
ZA (1) ZA966760B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006081A1 (en) * 1994-08-18 1996-02-29 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
TR199800208T1 (enExample) * 1995-08-11 1998-05-21 Pfizer Inc.
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
MXPA03001472A (es) 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
MXPA04003541A (es) * 2001-10-19 2004-07-22 Toyama Chemical Co Ltd Derivados de eter alquilo o sus sales.
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2305672B1 (en) 2008-06-13 2019-03-27 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9567341B2 (en) 2014-09-15 2017-02-14 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
EP3197440A4 (en) * 2014-09-22 2018-04-18 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
JP6876625B2 (ja) 2015-06-01 2021-05-26 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1996006081A1 (en) * 1994-08-18 1996-02-29 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
TR199800208T1 (enExample) * 1995-08-11 1998-05-21 Pfizer Inc.

Also Published As

Publication number Publication date
PE4898A1 (es) 1998-03-16
CZ39098A3 (cs) 1999-02-17
SA96170171B1 (ar) 2006-05-20
OA10664A (en) 2000-11-06
CA2228752C (en) 2002-12-10
YU46196A (sh) 1999-07-28
GT199600051A (es) 1997-12-26
PL325050A1 (en) 1998-07-06
IL122649A (en) 2001-08-26
NO310458B1 (no) 2001-07-09
RO120134B1 (ro) 2005-09-30
CA2228752A1 (en) 1997-02-27
EP0843661B1 (en) 2002-03-27
EP0843661A1 (en) 1998-05-27
DE69620191D1 (de) 2002-05-02
DZ2083A1 (fr) 2002-10-23
US6008233A (en) 1999-12-28
HRP960372A2 (en) 1998-04-30
RU2140910C1 (ru) 1999-11-10
CN1198739A (zh) 1998-11-11
DK0843661T3 (da) 2002-07-22
KR100291882B1 (ko) 2001-10-26
MA23957A1 (fr) 1997-04-01
BR9610766A (pt) 1999-07-13
AP9600856A0 (en) 1996-10-31
ES2170857T3 (es) 2002-08-16
TNSN96104A1 (fr) 2005-03-15
IL122649A0 (en) 1998-08-16
AU5908496A (en) 1997-03-12
NO980574D0 (no) 1998-02-10
CN1615861A (zh) 2005-05-18
AU710984B2 (en) 1999-10-07
TR199800208T1 (enExample) 1998-05-21
BG63678B1 (bg) 2002-09-30
NO980574L (no) 1998-02-10
UA59341C2 (uk) 2003-09-15
MX9801149A (es) 1998-05-31
CZ296236B6 (cs) 2006-02-15
PL185603B1 (pl) 2003-06-30
HUP9802862A3 (en) 1999-05-28
HUP9802862A2 (hu) 1999-04-28
SK16698A3 (en) 1999-06-11
KR19990036321A (ko) 1999-05-25
CO4750830A1 (es) 1999-03-31
IS4643A (is) 1997-12-30
RS49521B (sr) 2006-10-27
SK284209B6 (en) 2004-11-03
AP755A (en) 1999-08-02
TW495502B (en) 2002-07-21
PT843661E (pt) 2002-07-31
JPH10510552A (ja) 1998-10-13
IS1945B (is) 2004-08-13
DE69620191T2 (de) 2002-07-18
NZ309134A (en) 1999-09-29
WO1997007098A1 (en) 1997-02-27
ATE215072T1 (de) 2002-04-15
ZA966760B (en) 1998-02-09
AR004676A1 (es) 1999-03-10
BG102289A (en) 1998-09-30
JP3099072B2 (ja) 2000-10-16

Similar Documents

Publication Publication Date Title
HRP960372B1 (en) (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate
ZA9610858B (en) Heteroclyclic compounds.
ZA985875B (en) Azetidines.
ZA966773B (en) Sulfonyl-or sulfinyl-benzoylguanidin derivate.
ZA966956B (en) Fungicidal mixtures.
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA962753B (en) 1,3-Dihydro-2H-imidazol-2-one derivatives.
ZA964560B (en) Anit-viral compounds.
ZA967684B (en) Fungicidal mixtures.
ZA966957B (en) Fungicidal mixtures.
ZA969796B (en) Fungicidal compounds.
ZA966960B (en) Fungicidal mixtures.
ZA966955B (en) Fungicidal mixtures.
GB2289775B (en) I.S Machine
ZA964565B (en) Pyridiniminyl-1,2-benzisoxazoles and -benzisothiazoles
EP0664466A3 (en) Connector pin.
ZA969127B (en) Fungicidal compounds.
ZA966958B (en) Fungicidal mixtures.
ZA966959B (en) Fungicidal mixtures.
SI0843661T1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
ZA966961B (en) Fungicidal mixtures.
ZA969927B (en) 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives.
ZA961046B (en) Fungicidal composition.
IT1269022B (it) Tappo per operazioni di sfecciatura.
AU4256896A (en) Fungicidal 1,3,4-oxathiazol-2-ones

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060426

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20070810